DAPA-HF: Dapagliflozin Benefits Regardless of Age, HF Severity DAPA-HF: Dapagliflozin Benefits Regardless of Age, HF Severity

The SGLT2 inhibitor showed about the same effect on its clinical primary end point in the very elderly and across all degrees of symptom status at baseline in two new analyses.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news